Statera Biopharma, Inc. (STAB)
0.0001
0.00 (0.00%)
USD |
OTCM |
Dec 12, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0055M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.0% |
Profile
| Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO. |
| URL | http://www.staterabiopharma.com |
| Investor Relations URL | https://www.staterabiopharma.com/investors/ |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 17, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO. |
| URL | http://www.staterabiopharma.com |
| Investor Relations URL | https://www.staterabiopharma.com/investors/ |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | May. 17, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |